Payment overview · 2025
General Payments
$3,678.86
48 reported records · 15 companies
Healthcare provider profile · identity verified
Michael C Foster, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Interventional Cardiology · COLUMBIA, SC · NPI 1780625269
Verified facts
What the public records show
CMS Open Payments records show Michael C Foster, MD received $3,678.86 in general payments during 2025 across 48 reported records.
Medtronic, Inc. accounted for 42.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 239 claims for Eliquis by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 106 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 239 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$1,553.61 | 42.2% | 15 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $906.13 | 24.6% | 9 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $301.20 | 8.2% | 4 | 2025 |
| Teleflex LLC | Unresolved — no canonical attribution shown | $227.91 | 6.2% | 3 | 2025 |
| Recor Medical Inc | Unresolved — no canonical attribution shown | $166.26 | 4.5% | 2 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $138.86 | 3.8% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $107.35 | 2.9% | 1 | 2025 |
| CARDIVA MEDICAL, INC. | Unresolved — no canonical attribution shown | $79.04 | 2.1% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $44.43 | 1.2% | 2 | 2025 |
| Penumbra, Inc. | Unresolved — no canonical attribution shown | $41.49 | 1.1% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $35.23 | 1.0% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $24.38 | 0.7% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $18.73 | 0.5% | 1 | 2025 |
| CORDIS US CORP. | Unresolved — no canonical attribution shown | $18.65 | 0.5% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $15.59 | 0.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,533.33 | 40 |
| Travel and Lodging | $1,145.53 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| SYMPLICITY G3 Normalized: symplicity g3 |
Device | Medtronic, Inc. | $1,367.16 | 11 | 2025 |
Source payment records
|
|||||
| AVVIGO Guidance System Normalized: avvigo guidance system |
Device | Boston Scientific Corporation | $627.68 | 5 | 2025 |
Source payment records
|
|||||
| COREVALVE EVOLUT R Normalized: corevalve evolut r |
Device | Medtronic, Inc. | $186.45 | 4 | 2025 |
Source payment records
|
|||||
| Paradise Ultrasound Renal Denervation System Normalized: paradise ultrasound renal denervation system |
Device | Recor Medical Inc | $166.26 | 2 | 2025 |
Source payment records
|
|||||
| SAPIEN 3 Ultra RESILIA Normalized: sapien 3 ultra resilia |
Device | Edwards Lifesciences Corporation | $138.86 | 1 | 2025 |
Source payment records
|
|||||
| OptiCross Normalized: opticross |
Device | Boston Scientific Corporation | $134.57 | 1 | 2025 |
Source payment records
|
|||||
| TURNPIKE Normalized: turnpike |
Device | Teleflex LLC | $129.87 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $107.35 | 1 | 2025 |
Source payment records
|
|||||
| General - Vascular Access Normalized: general vascular access |
Device | Boston Scientific Corporation | $98.32 | 1 | 2025 |
Source payment records
|
|||||
| SUPERCROSS Normalized: supercross |
Device | Teleflex LLC | $70.17 | 1 | 2025 |
Source payment records
|
|||||
| CARDIVA VASCADE 6/7F VCS Normalized: cardiva vascade 6 7f vcs |
Device | CARDIVA MEDICAL, INC. | $60.86 | 3 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $44.43 | 2 | 2025 |
Source payment records
|
|||||
| Indigo System Normalized: indigo system |
Device | Penumbra, Inc. | $41.49 | 2 | 2025 |
Source payment records
|
|||||
| General - Atherectomy Normalized: general atherectomy |
Device | Boston Scientific Corporation | $36.22 | 1 | 2025 |
Source payment records
|
|||||
| NAVITOR Normalized: navitor |
Device | Abbott Laboratories | $35.23 | 1 | 2025 |
Source payment records
|
|||||
| VASCBAND Normalized: vascband |
Device | Teleflex LLC | $27.87 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $24.38 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $18.73 | 1 | 2025 |
Source payment records
|
|||||
| MYNX CONTROL Normalized: mynx control |
Device | CORDIS US CORP. | $18.65 | 1 | 2025 |
Source payment records
|
|||||
| CARDIVA VASCADE MVP VVCS 6-12F Normalized: cardiva vascade mvp vvcs 6 12f |
Device | CARDIVA MEDICAL, INC. | $18.18 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $15.59 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $9.34 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
239 | 59 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
106 | 21 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
239 | 59 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Metoprolol Succinate | Metoprolol Succinate | 438 | 140 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 345 | 102 |
| Atorvastatin Calcium | Atorvastatin Calcium | 322 | 96 |
| Clopidogrel | Clopidogrel Bisulfate | 253 | 69 |
| Eliquis | Apixaban | 239 | 59 |
| Amlodipine Besylate | Amlodipine Besylate | 165 | 53 |
| Spironolactone | Spironolactone | 151 | 49 |
| Carvedilol | Carvedilol | 149 | 42 |
| Entresto | Sacubitril/Valsartan | 138 | 31 |
| Furosemide | Furosemide | 126 | 48 |
| Jardiance | Empagliflozin | 106 | 21 |
| Nitroglycerin | Nitroglycerin | 105 | 70 |
| Lisinopril | Lisinopril | 93 | 31 |
| Repatha Sureclick | Evolocumab | 93 | 19 |
| Xarelto | Rivaroxaban | 87 | 19 |
| Ezetimibe | Ezetimibe | 85 | 28 |
| Losartan Potassium | Losartan Potassium | 73 | 23 |
| Potassium Chloride | Potassium Chloride | 73 | 30 |
| Amiodarone Hcl | Amiodarone Hcl | 70 | 25 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 67 | 21 |
| Farxiga | Dapagliflozin Propanediol | 63 | 16 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 43 | 13 |
| Metoprolol Tartrate | Metoprolol Tartrate | 42 | 18 |
| Hydrochlorothiazide | Hydrochlorothiazide | 39 | 16 |
| Valsartan | Valsartan | 36 | 12 |
| Ranolazine Er | Ranolazine | 35 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 31 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 29 | 12 |
| Simvastatin | Simvastatin | 27 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 26 | suppressed |
| Praluent Pen | Alirocumab | 26 | suppressed |
| Edarbyclor | Azilsartan Med/Chlorthalidone | 25 | suppressed |
| Brilinta | Ticagrelor | 24 | suppressed |
| Ramipril | Ramipril | 24 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 23 | suppressed |
| Fenofibrate | Fenofibrate | 22 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 20 | suppressed |
| Clonidine | Clonidine | 19 | suppressed |
| Nifedipine Er | Nifedipine | 18 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 18 | suppressed |
| Ozempic | Semaglutide | 18 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 17 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 17 | suppressed |
| Minoxidil | Minoxidil | 16 | suppressed |
| Multaq | Dronedarone Hcl | 16 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 16 | suppressed |
| Vascepa | Icosapent Ethyl | 16 | suppressed |
| Atenolol | Atenolol | 15 | suppressed |
| Metolazone | Metolazone | 15 | suppressed |
| Livalo | Pitavastatin Calcium | 14 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Eplerenone | Eplerenone | 12 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 12 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 12 | suppressed |
| Torsemide | Torsemide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,678.86 · 48 records | Medtronic, Inc. | AVVIGO Guidance System, CAMZYOS, CARDIVA VASCADE 6/7F VCS, CARDIVA VASCADE MVP VVCS 6-12F, COREVALVE EVOLUT R, General - Atherectomy, General - Vascular Access, Indigo System, MYNX CONTROL, NAVITOR, OptiCross, Paradise Ultrasound Renal Denervation System, REPATHA, SAPIEN 3 Ultra RESILIA, SUPERCROSS, SYMPLICITY G3, TURNPIKE, VASCBAND, VYNDAQEL, WATCHMAN FLX, Wegovy, ZEPBOUND | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with E.R. Squibb & Sons, L.L.C.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error